Our Investors

Investing in


BGF and Cambridge Innovation Capital joined existing investors Parkwalk, Wren Capital and Cambridge Enterprise, in PredictImmune’s Series B funding round, which completed in July 2019. The £10m investment, was a follow on to the Series A equity financing of £4.7m and has cemented PredictImmune’s solid financial position, enabling the Company to focus on continued global commercial expansion and expand its horizons in terms of product development.